Not available outside of the UK & Ireland.

Application

Tissue plasminogen activator has been used in a study to assess treatment risks of intracranial hemorrhage among patients with acute ischemic stroke. Tissue plasminogen activator has also been used in a study to investigate the successful treatment of early thrombosis of HeartWare left ventricular assist devices with intraventricular thrombolytics. Human tissue plasminogen activator has been used to study the effect of tyrosinase-related protein 2 (TRP-2) expression on melanin production in sheep.

Biochem/physiol Actions

tPA is a potent activator of fibrinolysis and converts plasminogen into plasmin and also initiates cell signaling. The plasminogen activation system may also be associated with degradation of amyloid fibrils. It is also known to mediate inflammatory and extracellular matrix remodeling processes and is predicted to participate in disease progression of intracranial aneurysm indicating brain vascular malformations. Upregulation of the gene is observed in aortic aneurysms.

General description

Tissue plasminogen activator (tPA) is a protease of the S1 family (trypsin family) and is found in a wide variety of mammalian tissues, especially endothelial cells. tPA is secreted as a single chain precursor, which is cleaved to a two-chain form by plasmin. Supplied in the single chain form with a molecular weight of ~70kDa. The Tissue Plasminogen Activator (tPA) gene is mapped to human chromosome 8p11.21 and encodes a protease of 69kDa majorly containing serine amino acid residue. It is predominantly expressed in endothelial cells.

Legal Information

TWEEN is a registered trademark of Croda International PLC

Physical form

Lyophilized powder, from 100 mM PBS (pH 7.4), 3.5 mg/mL L-arginine, and 0.001% Tween^® 80

Preparation Note

Reconstitute with dH2O to a final concentration of 1 mg/mL (e.g. 100 µg should be reconstituted in 100 µL).